These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 4009437)

  • 1. Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs.
    Garrett ER; Altmayer P
    J Pharm Sci; 1985 Mar; 74(3):295-9. PubMed ID: 4009437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability studies of etofibrate in rhesus monkeys.
    Waller AR; Chasseaud LF; Taylor T; Schatton W
    Arzneimittelforschung; 1985; 35(2):489-92. PubMed ID: 4039571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmolysis, red blood cell partitioning, and plasma protein binding of etofibrate, clofibrate, and their degradation products.
    Altmayer P; Garrett ER
    J Pharm Sci; 1983 Nov; 72(11):1309-18. PubMed ID: 6644594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictions of stability in pharmaceutical preparations XIX: Stability evaluation and bioanalysis of clofibric acid esters by high-pressure liquid chromatography.
    Garrett ER; Gardner MR
    J Pharm Sci; 1982 Jan; 71(1):14-25. PubMed ID: 7057373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Stability of antilipidemic etofibrate and its metabolites towards gastrointestinal and blood hydrolases (author's transl)].
    Oelschläger H; Rothley D; Ewert M; Nachev P
    Arzneimittelforschung; 1980; 30(6):984-8. PubMed ID: 7191278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.
    Anderson P; Norbeck HE
    Eur J Clin Pharmacol; 1981; 21(3):209-14. PubMed ID: 7318880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism.
    Herrera E; Lasunción MA; Castro M; Gómez-Coronado D; Martín A; Quack G
    Biochim Biophys Acta; 1988 Nov; 963(1):42-52. PubMed ID: 3179329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers.
    Abshagen U; Spörl-Radun S; Marinow J
    Eur J Clin Pharmacol; 1980 Apr; 17(4):305-8. PubMed ID: 6995131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetics of antilipemic agents. 4. Biotransformation of the antilipemic agent ciprofibrate (2-(4-(2,2-dichlorcyclopropyl)-phenoxy)-2-methylpropionic acid)].
    Oelschläger H; Rothley D; Schmidt W
    Arch Pharm (Weinheim); 1988 Jun; 321(6):367-70. PubMed ID: 3178437
    [No Abstract]   [Full Text] [Related]  

  • 10. Concentration of clofibric acid in blood after the administration of delayed-release form of etofibrate.
    Vazquez Lopez F; Armijo Castro F; Pire Solis I; Gutierrez Fuentes JA
    Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):31-5. PubMed ID: 3557726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of etofibrate on platelet function: in vitro studies in human plasma.
    Ortega MP; Sunkel C; Armijo M; Priego JG
    Thromb Res; 1980 Aug; 19(3):409-16. PubMed ID: 7001672
    [No Abstract]   [Full Text] [Related]  

  • 12. "In vitro" metabolism of bezafibrate by rat liver.
    Maffei FR; Carini M; Bertuletti R; Tofanetti O
    Pharmacol Res Commun; 1981 Feb; 13(2):121-32. PubMed ID: 7220572
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels.
    Paoletti R; Franceschini G; Sirtori CR
    Am J Cardiol; 1983 Aug; 52(4):21B-27B. PubMed ID: 6351577
    [No Abstract]   [Full Text] [Related]  

  • 14. Relative bioavailability of etofibrate. A comparison of an acute and a new sustained release formulation.
    Johnson KI; Hoppe HJ; Schatton W
    Arzneimittelforschung; 1984; 34(12):1785-7. PubMed ID: 6543315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies with etofibrate in the rat. Part II: A comparison of the effects of prolonged and acute administration on plasma lipids, liver enzymes and adipose tissue lipolysis.
    Bocos C; Castro M; Quack G; Herrera E
    Biochim Biophys Acta; 1993 Jul; 1168(3):340-7. PubMed ID: 8323974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man.
    Emudianughe TS; Caldwell J; Sinclair KA; Smith RL
    Drug Metab Dispos; 1983; 11(2):97-102. PubMed ID: 6133730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacology and mechanism of action of etofibrate].
    Schatton W
    Med Welt; 1982 Sep; 33(38):1310-4. PubMed ID: 6752630
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form.
    Ledermann H; Kaufmann B
    J Int Med Res; 1981; 9(6):516-20. PubMed ID: 7319135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lowering lipids rapidly and permanently with etofibrate].
    von Bock und Polach U
    Med Klin; 1982 Jan; 77(3):35-8. PubMed ID: 7057729
    [No Abstract]   [Full Text] [Related]  

  • 20. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L; Mingrone G; Ghirlanda G; Manna R; Rebuzzi A; Pala MA; Greco AV
    Minerva Med; 1980 Feb; 71(4):273-8. PubMed ID: 7354946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.